There is epidemiological evidence that vitamin D may be an important determinant of prostate cancer risk. Several studies have shown recently that inherited polymorphisms in the 3 0 -untranslated region (3 0 UTR) of the vitamin D receptor gene may be linked with prostate cancer risk and aggressive prostate cancer. This study analysed the vitamin D receptor gene polymorphisms in the 3 0 UTR, characterized by restriction enzymes BsmI, ApaI and TaqI, in Japanese prostate cancer patients to test whether the three polymorphisms are associated with risk of prostate cancer in the Japanese population, where the frequency of prostate cancer is much lower than in Western countries.
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Method
We studied 222 prostate cancer patients and 209 benign prostatic hyperplasia patients, 128 male controls aged over 60 y who did not show evidence of prostate cancer or benign prostatic hyperplasia and 198 female controls. A polymerase chain reaction (PCR)-restriction fragment length polymorphism method was used to determine the three Bsml, ApaI and TaqIVDR gene polymorphisms.
Results
As for the BsmI polymorphism, heterozygosity or homozygosity for the absence of the BsmI restriction site in the 3 0 UTR was associated with one-third of the risk of prostate cancer (P`0.0001; OR 3.44; 95% CI 2.76±4.29) and half the risk of benign prostatic hyperplasia (P`0.0005; OR 2.27; 95% CI 1.80±2.86), compared with the male controls. Furthermore, signi®cant differences in BsmI allelic frequency and genotype were found between the female and the male controls. The TaqI and ApaI polymorphisms did not show any signi®cant association with either prostate cancer or benign prostatic hyperplasia.
Conclusion
The BsmI polymorphism in the vitamin D receptor gene may play a signi®cant role in protecting against prostate cancer and benign hyperplasia. The presence of at lest one allele that is absent from the BsmI restriction site may be signi®cantly associated with protection against prostate cancer and benign prostatic hyperplasia. Because of the racial difference in the strength of the linkage disequilibrium between the three polymorphisms, further studies may be required to apply the present results to other races.
